Rhinitis often precedes and is a co-existing disease in workers with occupational asthma. Therefore, understanding occupational rhinitis may result in new diagnostic and therapeutic strategies that may help prevent the development of asthma. We previously developed a murine model of toluene diisocyanate (TDI) rhinitis displaying increased expression of IL-4, IL-5, IL-13, IFNGamma, TNFalpha and IL-1Beta as well as extensive eosinophil infiltration into the nasal mucosa. Whole-genome expression analysis demonstrated that genes involved in inflammatory cell recruitment/movement and, specifically, chemotaxis, chemokine activation and chemokine receptor binding were differentially expressed in the nasal mucosa of mice with TDI rhinitis. The chemokine receptor 3 (Ccr3) pathway is important for the recruitment of eosinophils and Th2 lymphocytes to sites of allergic inflammation. We hypothesized that the Ccr3:ligand axis is activated in TDI rhinitis leading to the recruitment of Th2 lymphocytes and eosinophils. Mice were exposed to 50 ppb TDI vapor via inhalation for 12 consecutive weekdays and real-time PCR was used to analyze the expression of chemokine, chemokine receptor and immune genes in the nasal mucosa 24 hours following the final exposure. Expression of Ccr3 and its ligands, Ccl11 (eotaxin I) and Ccl24 (eotaxin II) were upregulated in the nasal mucosa following TDI inhalation. Administration of neutralizing anti-Ccr3 antibodies prior to TDI exposure prevented the upregulation of Ccl11 and Ccl24. In addition, neutralization of Ccr3 markedly reduced TDI-induced changes in IL-4, IL-5, IL-13, TNFAlpha and IL-1Beta expression. These results support the hypothesis that Ccr3 is an important mediator of inflammation in TDI rhinitis.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.